Nabriva Therapeutics’ drug application for its antibiotic Xenleta recently got the approval from the Food and Drug Administration. The antibiotic treats community-acquired bacterial pneumonia (CABP), a leading cause of infection-related deaths in the United States.
Based in King of Prussia, Nabriva claims about 5 million cases of pneumonia are reported in the United States each year, and pneumonia is the fifth-leading cause of hospitalizations, writes John George in the Philadelphia Business Journal.
[uam_ad id=”54865″]
Nabriva (NASDAQ: NRBV), led by CEO Ted Schroeder, is based in Ireland and has its U.S. headquarters in King of Prussia.
Nabriva said Xenleta is part of a new class of antibiotics called pleuromutilins that works differently from older antibiotics. Its antibiotic, the company explained, is a semi-synthetic compound designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow.
The last time the FDA approved a new class of antibiotics for CABP was 2000.
To read the complete story click here.
[uam_ad id=”54875″]
